Drug intelligence / Profile preview

NBX-400

Development stage: Preclinical
Lead developer: Neurala Biosciences
Modality: Small Molecules

Overview

**NBX-400** is a Neurala Biosciences preclinical small-molecule DMT-harmala neuromedicine program being optimized for an undisclosed neurological indication. Neurala describes the candidate as having a sub-psychedelic psychoactive profile; its precise chemical composition, molecular targets, route of administration, dosage form, and detailed mechanism of action have not been publicly disclosed.

Targets

HTR2A (Serotonin receptor 5-HT2A)MAOA (Monoamine oxidase A)

Beyond the preview

Go deeper on NBX-400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBX-400.

Explore the full profile